1. A Spanish Human Proteome Project (sHPP) La Cristalera, Miraflores de la Sierra, Madrid, August 28-29th, 2012 Juan P Albar, ProteoRed-ISCIII, CNB-CSIC

2. A SPANISH HUMAN PROTEOME PROJECT (SHPP) Preliminary proposal Index 1.Introduction International context Chromosome/gene centric approach The HPP technological pillars Protein annotation and database compilation 2.The Spanish Participation in the Human Proteome Project 3.General and Specific Aims General aims Specific aims 4.Members of the Spanish Consortium Description of the groups ProteoRed presence in the Spanish consortium 5.Working Plan Work package list Work package description 6.Financing 7.Spanish Consortium Structure 8.Benefit for Spain

3. Spanish HPP Consortium: Current Developments on the Characterization of the Proteins Encoded by the Chromosome 16" 5th C-HPP Consortium Workshop The Chromosome-Centric Human Proteome Project May 5, 2012, Beijing Juan-Pablo Albar (Chair) Francisco Blanco (Co-Chair) Fernando Corrales (Co-Chair)

4. A Spanish Human Proteome Project (sHPP) Preliminary proposal San Sebastian, July 9th, 2012 Juan P Albar, ProteoRed-ISCIII, CNB-CSIC

5. The Human Proteome Project Launch Sydney HUPO2010 23 September 2010 Geneva HUPO2011 12 September 2011 Sydney September 23Human Proteome Project

6. The Mission of the HPP HPP will deliver a comprehensive map of the human proteins in their biological context. HPP will provide tools for the scientific community that will allow each scientist to design experiments in a better way, as the Human Genome Project did. HPP will inspire, beyond the scientific community, other stakeholders for diagnosis, prevention, therapy and cure of diseases and improved health worldwide. Sydney September 23Human Proteome Project

7. A gene-centric proteome project Map the human proteins (gene by gene): Molecular (isoforms) Sub-cellular (localization) Cells, tissues and organs (expression) Interaction networks Plasma/serum (abundance) Use all available technology platforms: Mass spectrometry Antibodies (immunotechnologies) Gene fusions (GFP) Sydney September 23Human Proteome Project

8. Knowledge-based resource (normal profiles) For each protein Antibody-based proteomics involved in all areas All data available to the public (with no IPR restrictions) Sydney September 23Human Proteome Project

9. Knowledge-based resource (disease profiles) For each protein Disease specific projects Investigator-driven Possible to seek IPR-protection Sydney September 23Human Proteome Project

12. The Human Proteome Project Launch "Protein Maps and Interactions in Human Body"  It is the time to start the "Human Proteome Project" by international and national collaborations.  HUPO encourages/urges each national public funding agency to identify their preferred pathway to support aspects of this extraordinary coordinated Project. Sydney September 23Human Proteome Project

15. C-HPP teams by April 24th, 2012. The C-HPP Consortium internal information

16. Young-Ki Paik J. Proteome Res. 2012, 11, 2005−2013 The Chromosome–Centric Human Proteome Project

18. HPP technologic pillars Legrain et al. MCP 2011

20. Flow of the overall procedures of the C-HPP work

23. Schematic overview of the gene-centric Proteome sequencing Diagnosis & Personalized Drug Development CHROMOSOME16 CONSORTIUM DELIVERIES

24. Spanish HPP Consortium: Current Developments on the Characterization of the Proteins Encoded by the Chromosome 16" 5th C-HPP Consortium Workshop The Chromosome-Centric Human Proteome Project May 5, 2012, Beijing Juan-Pablo Albar (Chair) Francisco Blanco (Co-Chair) Fernando Corrales (Co-Chair)

25. HPP Spanish contribution Spanish HPP Consortium (SHPP) has been recognized internationally as one of the best positioned consortia to address the huge challenge represented by the definition of the whole protein set encoded by all genes on a given chromosome. Our participation in HPP, although initially by taking part first proposes in a multinational project, in collaboration Sweden and others, which focused in the definition of the sub-proteome derived from chromosome 19 genes, now we have proposed, and it has been accepted by HUPO, to built our contribution focused on the characterization of the Chromosome 16 protein coding genes. This chromosome contains many genes and proteins involved in the development of a broad range of diseases with a significant impact on Spaniards and our healthcare system. These diseases include neurological disorders, tubular myopathy, centronuclear myopathy, familial hemiplegic migraine and age-related diseases like Parkinsonr, cardiovascular disease, arthritis and cancer.

26. Chromosome 16

28. 1.Bioinformatic analysis of chromosome 16. 2.Cell type(s) selection. Trascriptomic and proteomic detailed analysis. 3.Expression, purification and characterization of proteins encoded by chromosome 16 that have not been described so far. 4.Development of MRM methods for the quantification of the most abundant protein species encoded by each of the chromosome 16 genes. 5.Identification, characterization and quantification of protein variants from chromosome 16 genes. 6.Definition of SOP 7.Development of bioinformatic environment. 8.Biobanking. 9.Configuration of the B-D pilar for the Spanish HPP consortium. Chromosome 16 general aims

29. Top 15 Biofunctions represented in chromosome 16. IPA analysis

30. Genes on Chromosome 16 More than 85 % of protein coding genes of chromosome 16 are expressed in lymphoid cells, epitelial cells and fibroblasts.

31. OMIM NEURODEGENERATIVE CANCER OBESITY AUTOINMUNE DISEASES Metabolism Mitochondria Inflammation Diseases mapping on Chromosome 16

32. External repositories Development of bioinformatic environment: Spanish HPP will join the different resources to provide an unique enquiring system PAtlas NProt GPMDB PRIDE UProt Upcoming Proteomics results Data standards submission (ProteomeXchange) + + Emsembl

33. Data Standards – PSI framework Spanish Consortium Bioinformatics pipeline Mass Spectra Raw data MzMl/TraML Protein/Pepti des Search Engines MzIdentml Quantitation Vendor/Free software MzQuantml Data Reporting – ProteoRed MIAPE Web toolkit MIAPE MS/MSI PRIDE Data Reporting – with stable release MIAPEQuant PRIDEQuant? ?? Data validation and submission ProteomeXcahnge

34. Characterize the transcriptome to define the actual chr16’s gen set expressed and most importantly which genes are not expressed in the three selected cell types. Characterize the proteome in detail. Expression, purification, and characterization of 22 unknown proteins available in NAPPA collection. Development of SRM quantitative assays.  Proteins (862) will be distributed in known (562) and unknown groups (300) and the study will be performed along 3 years, starting in 2012 (214 proteins).  Protein packs will be assigned to each of the 8 MRM groups (24), including equal proportion of known (20, with different range of theoretical difficulty) and unknown proteins (4).  Unknown proteins will be first searched by targeted discovery (TD) and relevant information resulting from this studies will be used to design MRM assays. TD groups (9) will analyze 54 proteins the first year.  Each group will use the master sample (this might require the use of synthetic peptides during the refinement steps). TD will be done in all three selected cell lines. Regarding MRM, a pool of the three cell lines will be used for the 20 known proteins. Decision on using a pool or a particular cell line for the unknown proteins will be taken in light of the results from TD.  Once developed, the assays will be validated by 2 additional groups. Finally, the quantitative assay will be set up using heavy peptides. Definition of Bioinformatic standards and SOPs. Definition of Biobanking strategy, standards... in collaboration with the Spanish Biobanking Platform. Workplan proposal

35. 201520162017 Biobanking Validation of MRM assays (3 groups, immunoreagents, correlation with gene expression) Clinical samples. Disease-related changes on protein abundance. Biomarkers Bioinfirmatic study MRM for 204 proteins MRM for 329 proteins SOP, bioinformatic procedures, formats, data banks, etc. 201220132014 Biobanking MRM for 329 proteins Validation of MRM assays (3 groups, immunoreagents, correlation with gene expression) Clinical samples. Disease-related changes on protein abundance. Biomarkers Chromosome 16 timeline Transcriptomic study Master sample Targeted discovery (300 proteins)

36. SHPP-16 Platform C-HPP Platform BD-HPP Proteo-Red/ISCIII 111 Unknow Proteins 735 Know Proteins Biology Cells/Tissues Diseases: Pathogenesis Diagnostic Prognosis Treatment BIOBANK/ISCIII

37. Who we are ProteoRed organization has played an active role in the HUPO- PSI activities, always in close relation with the developments and reviews of different MIAPE modules. ProteoRed, an initiative for the coordination, integration and development of 20 proteomics facilities placed all over Spain. http://www.proteored.org ProteoRed use to organize and participate in multi-centric studies that aims to evaluate the robustness and reproducibility of different proteomics workflows.

38. Node 2 J. Mato - CIC-bioGUNE F. Corrales – CIMA JM. Arizmendi - UPV Central Structure JP. Albar - CNB J. Mato - CIC-bioGUNE J. Abian - LP-CSIC/UAB Assoc. to Node 1 I. Casal - CIB Assoc. To Node 5 P. Carrasco - UV Node 5 M. Sánchez del Pino – CIPF R. Bru - UA Node6 JA. Bárcena - UCO Node 1 JP. Albar - CNB C. Gil - PCM-UCM A. Marina - CBMSO Node 4 X. Bustelo - CIC Node 3 J. Abian - LP-CSIC/UAB J. Arribas - HUVH S. Martínez - PCB D. Andreu - UPF FX. Avilés - IBB UAB O. Bachs - UB *. * - Assoc. to node 4 F.J. Blanco - INIBIC Portugal Ana Coelho - ITQB Deborah Penque - ProCura Geneva Jean Charles Sanchez - UG Geographical organization

39. BD-HPP Platform Coordinator: Francisco J. Blanco Clinical Research Biomarkers (D/P/P/T) 1st Phase: Known Proteins 2nd Phase: Unknown Proteins Cancer Chair: Co-Chair: I. Casal) Cancer Chair: Co-Chair: I. Casal) CAIBER/ISCIII Neurologic Disorders Chair: A. Lopez- Munain Co-chair:JM Arizmendi Rheumatic Diseases: Chair: FJ. Blanco Co-Chair: JP Albar Rheumatic Diseases: Chair: FJ. Blanco Co-Chair: JP Albar Obesity Chair: J Prieto Co-Chair: F. Corrales Obesity Chair: J Prieto Co-Chair: F. Corrales RETIC of Cancer CIBERNed RETIC of Rheumatic CIBER- Obesity BIOBANK/ISCIII SHPP-16 Cardiovascular Diseases: Chair: L Rodriguez-Padial Co-Chair: F. Vivanco Cardiovascular Diseases: Chair: L Rodriguez-Padial Co-Chair: F. Vivanco RETIC- Cardiov. Infectiious Diseases: Chair: J Fortun Co-Chair: C. Gil Infectiious Diseases: Chair: J Fortun Co-Chair: C. Gil

40. BD-HPP Platform Diseases Cancer Chair: Cristobal Belda Co-Chair: Ignacio Casal Colon Cancer Brain Tumours Breast Cancer Cancer Chair: Cristobal Belda Co-Chair: Ignacio Casal Colon Cancer Brain Tumours Breast Cancer Neurologic Disorders Chair: Adolfo Munain Co-chair:JM Arizmendi Parkinson Diseases Muscular Distrophy Rheumatic Diseases: Chair: FJ. Blanco Co-Chair: JP Albar Rheumatoide Arthritis SLE Osoteoarthritis Rheumatic Diseases: Chair: FJ. Blanco Co-Chair: JP Albar Rheumatoide Arthritis SLE Osoteoarthritis SHPP-16

41. BD-HPP Platform Diseases Obesity Chair: J Prieto Co-Chair:F. Corrales Non Alcoholic Faty Liver Diseases Obesity Chair: J Prieto Co-Chair:F. Corrales Non Alcoholic Faty Liver Diseases SHPP-16 Cardiovascular Diseases: Chair: L Rodriguez-Padial Co-Chair: F. Vivanco Atheroesclerosis Valvular Diseases Cardiovascular Diseases: Chair: L Rodriguez-Padial Co-Chair: F. Vivanco Atheroesclerosis Valvular Diseases Infectious Diseases: Chair: J Fortun Co-Chair: C. Gil Candidiasis Infectious Diseases: Chair: J Fortun Co-Chair: C. Gil Candidiasis

42. Proteins in Rheumatic Diseases

43. Biologic Samples

44. NATIONAL NETWORK BIOBANKS INSTITUTE OF INSTITUTE OF HEALTH CARLOS III RD09/0076/00066 HOSPITAL VALLE DE HEBRON RD09/0076/00076 HOSPITAL MARQUES DE VALDECILLA RD09/0076/00056 HOSPITAL DE BELLVITGE RD09/0076/00085 HOSPITAL VIRGEN DEL ROCIO RD09/0076/00008 HOSPITAL RAMON Y CAJAL RD09/0076/00103 HOSPITAL GREGORIO MARAÑON RD09/0076/00102 HOSPITAL CLINICO SAN CARLOS RD09/0076/00021 HOSPITAL LA FE RD09/0076/00073 HOSPITAL LA PAZ RD09/0076/00038 HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA RD09/0076/00043 RED DE BANCOS DE TUMORES DE ANDALUCIA RD09/0076/00108 INSTITUTO DE SALUD CARLOS III RD09/0076/00058 CENTRO SUPERIOR DE INVESTIGACION EN SALUD PUBLICA (CSISP) RD09/0076/00159 CENTRO VASCO DE TRANSFUSION Y TEJIDOS HUMANOS RD09/0076/00068 FUNDACION INBIOMED RD09/0076/00084 FUNDACION MD ANDERSON INTERNATIONAL ESPAÑA RD09/0076/00088 FUNDACION VASCA DE INNOVACION E INVESTIGACION SANITARIAS RD09/0076/00063 FUNDACION CENTRO DE INVESTIGACION PRINCIPE FELIPE RD09/0076/00133 UNIVERSIDAD DE SALAMANCA RD09/0076/00147 HOSPITAL VIRGEN DE LA VICTORIA RD09/0076/00002 HOSPITAL DE GETAFE RD09/0076/00072 COMPLEJO HOSPITALARIO MATERNO-INSULAR RD09/0076/00064 FUNDACION PUIGVERT RD09/0076/00057 HOSPITAL SAN JUAN DE DIOS ESPLUGUES RD09/0076/00113 FUNDACION CENTRO NAL DE INV. ONCOLOGICAS RD09/0076/00151 HOSPITAL DE BASURTO RD09/0076/00130 COMPLEJO HOSPITALARIO DE LEON RD09/0076/00041 HOSPITAL GENERAL DE ELCHE RD09/0076/00127 HOSPITAL DE FUENLABRADA RD09/0076/00029 HOSPITAL DE NAVARRA RD09/0076/00011 COMPLEJO HOSPITALARIO DE VIGO RD09/0076/00171 COMPLEJO HOSPITALARIO DE SANTIAGO RD09/0076/00032 COMPLEJO HOSPITALARIO DE A CORUÑA RD09/0076/00104 SAN JUAN DE DIOS. SERVICIOS DE SALUD MENTAL RD09/0076/00074 HOSPITAL VIRGEN DE LA SALUD RD09/0076/00062 HOSPITAL GENERAL DE ALICANTE RD09/0076/00028 CENTRO DE INVESTIGACIÓN DEL CÁNCER RD09/0076/00080 HOSPITAL VIRGEN MACARENA RD09/0076/00163 FUNDACION INSTITUTO VALENCIANO DE ONCOLOGIA RD09/0076/00149 HOSPITAL DE TXAGORRITXU RD09/0076/00148 HOSPITAL UNIVERSITARIO SAN CECILIO RD09/0076/00142 FUNDACION HOSPITAL ALCORCON RD09/0076/00049 HOSPITAL JOAN XXIII RD09/0076/00047 COMPLEJO HOSPITAL GENERAL DE ALBACETE RD09/0076/00101 FUNDACION JIMENEZ DIAZ RD09/0076/00065 HOSPITAL VIRGEN DE LA ARRIXACA RD09/0076/00123 HOSPITAL MIGUEL SERVET RD/09/0076/00010 HOSPITAL GERMANS TRIAS I PUJOL RD09/0076/00154 HOSPITAL DONOSTIA RD/09/0076/00036 HOSPITAL DEL MAR RD/09/0076/00081 HOSPITAL DE LA SANTA CRUZ Y SAN PABLO RD09/0076/00078 CLINICA UNIVERSITARIA DE NAVARRA RD/09/0076/00054 HOSPITAL SON DURETA RD09/0076/00118 HOSPITAL 12 DE OCTUBRE RD09/0076/00165 HOSPITAL VIRGEN DE LAS NIEVES RD09/0076/00150 HOSPITAL DE CRUCES RD/09/0076/00059 HOSPITAL ARNAU DE VILANOVA RD09/0076/00004 HOSPITAL CENTRAL DE ASTURIAS RD09/0076/00112 HOSPITAL CARLOS HAYA RD09/0076/00144 HOSPITAL REINA SOFIA RD09/0076/00111 HOSPITALARIO UNIVERSITARIO DE SALAMANCA RD/09/0076/00125 HOSPITAL DR. JOSEP TRUETA RD09/0076/00132 HOSPITAL CLINICO UNIVERSITARIO DE VALENCIA 4 3 11 12 27 1 2 7 8 1 1 1

45. HOSPITALES INSTITUTOS DE INVESTIGACIÓN CENTROS DE INVESTIGACIÓN REDES COOPERATIVAS CANCER Drs C. BELDA & I. CASAL CANCER Drs C. BELDA & I. CASAL Chr16-HPP Proteomics Platforms NEUROLOGICAL DISEASES Dr A. LOPEZ DE MUNAIN NEUROLOGICAL DISEASES Dr A. LOPEZ DE MUNAIN CARDIOVASCULAR DISEASES Dr F. VIVANCO & JLR: PADIAL CARDIOVASCULAR DISEASES Dr F. VIVANCO & JLR: PADIAL RHEUMATIC & MUSCLOSKELETAL DISEASES Dr. F. BLANCO RHEUMATIC & MUSCLOSKELETAL DISEASES Dr. F. BLANCO SPANISH NATIONAL BIOBANK NETWORK-ISCIII Dr M. MORENTE SPANISH NATIONAL BIOBANK NETWORK-ISCIII Dr M. MORENTE INFECTIOUS DISEASES Drs C. GIL & J. FORTÚN INFECTIOUS DISEASES Drs C. GIL & J. FORTÚN OBESITY/LIVER DISEASES Drs J. PRIETO & F. CORRALES OBESITY/LIVER DISEASES Drs J. PRIETO & F. CORRALES

46. HOSPITALES INSTITUTOS DE INVESTIGACIÓN CENTROS DE INVESTIGACIÓN REDES COOPERATIVAS ASOCIACIONES DE PACIENTES MINISTERIO DE INDUSTRIA MINISTERIO DE ECONOMIA Y COMPETITIVIDAD MINISTERIO DE SANIDAD MINISTERIO DE EDUCACIÓN FARMAINDUSTRIA ASEBIO INVERSIÓN PRIVADA PLATAFORMAS PROTEÓMICAS HPP COMUNIDADES AUTÓNOMAS EMPRESAS AFINES

47. Steering Committee Analytical (C-HPP) Gene/chromosome centric Analytical (C-HPP) Gene/chromosome centric B-D initiatives Disease centric B-D initiatives Disease centric Bioinformatics MS and Ab based quantitative methods Open access repositories MS and Ab based quantitative methods Open access repositories Hallmarks of disease Potential biomarkers and therapeutic targets Hallmarks of disease Potential biomarkers and therapeutic targets Clinical devices Personalized medicine Design of prototypes Quantitation of target proteins Design of prototypes Quantitation of target proteins MINECO Pharmas ISCIII Biotechs MINECO ISCIII CNB UCM CIB FJD CicBiogune CIMA CIPF UAB PCB Vall D’Hebron USAL La Paz INIVIC CNB UCM CIB FJD CicBiogune CIMA CIPF UAB PCB Vall D’Hebron USAL La Paz INIVIC

48. Board of Directors Project Manager Technical Director Finance Director WG 1 RU1a/1b WG 4 RU 2a/2h Working Groups Research Units WG 2 WG 3 WG 5 Executive Committee RU 3a/3g RU 4a/4e RU 5a/5g CHROMOSOME-16 CONSORTIUM STRUCTURE

49. WG 1.-Protein Micro Array & Peptide Standard Team RU1a (Protein Micro Array and Protein Expression Team) Dr. Manuel Fuentes CIC/IBMCC (USAL/CSIC), Salamanca RU1a (Protein Micro Array and Protein Expression Team) Dr. Manuel Fuentes CIC/IBMCC (USAL/CSIC), Salamanca RU1b (Peptide Standard Team) Dr. Juan P Albar CNB-CSIC, ProteoRed, Madrid RU1b (Peptide Standard Team) Dr. Juan P Albar CNB-CSIC, ProteoRed, Madrid Scientific Researchers: F. Roncal M. Lombardía Scientific Researchers: F. Roncal M. Lombardía

50. WG 2.-S/MRM-Protein Platform Team RU2a Dr. Juan P. Albar CNB-CSIC, ProteoRed, Madrid RU2a Dr. Juan P. Albar CNB-CSIC, ProteoRed, Madrid RU2b Dr. Fernando Corrales CIMA-UN ProteoRed, Pamplona RU2b Dr. Fernando Corrales CIMA-UN ProteoRed, Pamplona RU2c Dr. Francesc Canals V.H.I.O. ProteoRed, Barcelona RU2c Dr. Francesc Canals V.H.I.O. ProteoRed, Barcelona RU2d Dr. Concha Gil PCM-UCM ProteoRed, Madrid RU2d Dr. Concha Gil PCM-UCM ProteoRed, Madrid RU2e Dr. Manuel Sanchez del Pino UV ProteoRed, Valencia RU2e Dr. Manuel Sanchez del Pino UV ProteoRed, Valencia RU2f Dr. Fernando Vivanco / Dr. M.E Barderas FJD,Madrid/ HNP, Toledo RU2f Dr. Fernando Vivanco / Dr. M.E Barderas FJD,Madrid/ HNP, Toledo RU2g Dr. Francisco Blanco INIBIC, ProteoRed, La Coruña RU2g Dr. Francisco Blanco INIBIC, ProteoRed, La Coruña RU2h Dr. Silvia Barceló IACS, Zaragoza (Provisional) RU2h Dr. Silvia Barceló IACS, Zaragoza (Provisional) Scientific Researchers: M. Marcilla S. Gharbi A.Alpízar C. González Scientific Researchers: M. Marcilla S. Gharbi A.Alpízar C. González Scientific Researchers:

51. WG 3.-Protein Sequencing Team RU3f Dr. Jesus M. Arizmendi UPV ProteoRed, Bilbao RU3f Dr. Jesus M. Arizmendi UPV ProteoRed, Bilbao RU3e Dr. Ignacio Casal CIB-CSIC, ProteoRed, Madrid RU3e Dr. Ignacio Casal CIB-CSIC, ProteoRed, Madrid RU3d Dr. Eliandre de Oliveira PCB, ProteoRed, Barcelona RU3d Dr. Eliandre de Oliveira PCB, ProteoRed, Barcelona RU3c Dr. Manuel Sanchez del Pino UV, ProteoRed, Valencia RU3c Dr. Manuel Sanchez del Pino UV, ProteoRed, Valencia RU3b Dr. Joaquin Abian IIBB-CSIC ProteoRed, Barcelona RU3b Dr. Joaquin Abian IIBB-CSIC ProteoRed, Barcelona RU3a Dr. José M. Mato / Dr. Félix Elortza CIC- BioGUNE, ProteoRed, Bilbao RU3a Dr. José M. Mato / Dr. Félix Elortza CIC- BioGUNE, ProteoRed, Bilbao RU3g Dr. Juan P. Albar CNB-CSIC, ProteoRed, Madrid RU3g Dr. Juan P. Albar CNB-CSIC, ProteoRed, Madrid Scientific Researchers: A.Paradela R. Navajas Scientific Researchers: A.Paradela R. Navajas Scientific Researchers:

52. WG 4.-Bioinformatics Team RU4a Dr. Juan P Albar CNB-CSIC, ProteoRed, Madrid RU4a Dr. Juan P Albar CNB-CSIC, ProteoRed, Madrid RU4b Dr. Fernando Corrales CIMA-UN ProteoRed, Pamplona RU4b Dr. Fernando Corrales CIMA-UN ProteoRed, Pamplona RU4c Dr. Joaquin Abian IIBB-CSIC ProteoRed, Barcelona RU4c Dr. Joaquin Abian IIBB-CSIC ProteoRed, Barcelona RU4e Dr. Jesus M. Arizmendi UPV ProteoRed, Bilbao RU4e Dr. Jesus M. Arizmendi UPV ProteoRed, Bilbao RU4d Dr. Concha Gil PCM-UCM ProteoRed, Madrid RU4d Dr. Concha Gil PCM-UCM ProteoRed, Madrid Scientific Researchers: A.Medina S. M- Bartolomé Scientific Researchers: A.Medina S. M- Bartolomé Scientific Researchers:

53. WG 5.-Clinical Health Care & Biobanking Team (S_B/D-HPP) RU5g Dr. Manuel Morente SNBN, CNIO, Madrid (considered for inclusion in the consortium) RU5g Dr. Manuel Morente SNBN, CNIO, Madrid (considered for inclusion in the consortium) RU5d Dr. Adolfo López de Munain Inst. Biodonostia S. Sebastian RU5d Dr. Adolfo López de Munain Inst. Biodonostia S. Sebastian RU5c Dr. Rodríguez Padial/ Dr. Fernando Vivanco / Dr. M.E Barderas FJD, Madrid/HNP, Toledo RU5c Dr. Rodríguez Padial/ Dr. Fernando Vivanco / Dr. M.E Barderas FJD, Madrid/HNP, Toledo RU5b Dr. Cristobal Belda FSB, La Paz Hospital, Madrid (Provisional) RU5b Dr. Cristobal Belda FSB, La Paz Hospital, Madrid (Provisional) RU5a Dr. Francisco Blanco INIBIC, ProteoRed, La Coruña RU5a Dr. Francisco Blanco INIBIC, ProteoRed, La Coruña Scientific Researchers: RU5f Dr. Concha Gil PCM-UCM ProteoRed, Madrid RU5f Dr. Concha Gil PCM-UCM ProteoRed, Madrid RU5e Dr. Fernando Corrales CIMA-UN ProteoRed, Pamplona RU5e Dr. Fernando Corrales CIMA-UN ProteoRed, Pamplona Scientific Researchers:

54. WG5-Clinical Health Care & Biobanking Team RU5a-Dr. Francisco Blanco Instituto de Investigacion Biomedica (INIBIC), ProteoRed, La Coruña RU5b-Dr. Cristobal Belda (Provisional) Severiano Ballesteros Foundation La Paz Hospital, Madrid RU5c-Dr. Rodriguez Padial/Dr. Fernando Vivanco/ Dr. ME Barderas Jimenez Díaz Foundation (FJD), Madrid /National Paraplegics Hospital, Toledo Ru5d-Dr. Adolfo López de Munain Instituto Biodonostia, San Sebastian RU5e-Dr. Fernando Corrales/J. Prieto CIMA-University of Navarra RU5f-Dr. Concha Gil PCM-Computensis University (PCM-UCM), ProteoRed, Madrid RU5g-Dr. Manuel Morente (considered for inclusion in the consortium) Spanish National BioBanking Network CNIO, Madrid WG5-Clinical Health Care & Biobanking Team RU5a-Dr. Francisco Blanco Instituto de Investigacion Biomedica (INIBIC), ProteoRed, La Coruña RU5b-Dr. Cristobal Belda (Provisional) Severiano Ballesteros Foundation La Paz Hospital, Madrid RU5c-Dr. Rodriguez Padial/Dr. Fernando Vivanco/ Dr. ME Barderas Jimenez Díaz Foundation (FJD), Madrid /National Paraplegics Hospital, Toledo Ru5d-Dr. Adolfo López de Munain Instituto Biodonostia, San Sebastian RU5e-Dr. Fernando Corrales/J. Prieto CIMA-University of Navarra RU5f-Dr. Concha Gil PCM-Computensis University (PCM-UCM), ProteoRed, Madrid RU5g-Dr. Manuel Morente (considered for inclusion in the consortium) Spanish National BioBanking Network CNIO, Madrid WG4-Bioinformatics Team RU4a-Dr. Juan P Albar National Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid RU4b-Dr. Fernando Corrales CIMA-University of Navarra ProteoRed, Pamplona RU4c-Dr. Joaquin Abian IIBB, CSIC, ProteoRed, Barcelona RU4d-Dr. Concha Gil PCM-Computensis University (PCM-UCM), ProteoRed, Madrid RU4e-Dr. Jesus M. Arizmendi Basque Country University, ProteoRed, Bilba o WG4-Bioinformatics Team RU4a-Dr. Juan P Albar National Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid RU4b-Dr. Fernando Corrales CIMA-University of Navarra ProteoRed, Pamplona RU4c-Dr. Joaquin Abian IIBB, CSIC, ProteoRed, Barcelona RU4d-Dr. Concha Gil PCM-Computensis University (PCM-UCM), ProteoRed, Madrid RU4e-Dr. Jesus M. Arizmendi Basque Country University, ProteoRed, Bilba o WG2-S/MRM-Protein Platform Team RU2a-Dr. Juan P Albar National Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid RU2b-Dr. Fernando Corrales CIMA-University of Navarra, ProteoRed, Pamplona RU2c-Dr. Francesc Canals Vall d'Hebron Institut d'Oncologia (V.H.I.O.),ProteoRed, Barcelona RU2d-Dr. Concha Gil Madrid Science Park-Computensis University (PCM-UCM), ProteoRed, Madrid RU2e-Dr. Manuel Sanchez del Pino Felipe Princess Research Center (CIPF), ProteoRed, Valencia RU2f-Dr. Fernando Vivanco / Dr. ME Barderas Jimenez Díaz Foundation (FJD), Madrid /National Paraplegics Hospital, Toledo RU2g-Dr. Francisco Blanco Instituto de Investigacion Biomedica (INIBIC), ProteoRed, La Coruña RU2h-Dr Silvia Barceló Aragón Health Sciences Institute (IACS), Zaragoza WG2-S/MRM-Protein Platform Team RU2a-Dr. Juan P Albar National Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid RU2b-Dr. Fernando Corrales CIMA-University of Navarra, ProteoRed, Pamplona RU2c-Dr. Francesc Canals Vall d'Hebron Institut d'Oncologia (V.H.I.O.),ProteoRed, Barcelona RU2d-Dr. Concha Gil Madrid Science Park-Computensis University (PCM-UCM), ProteoRed, Madrid RU2e-Dr. Manuel Sanchez del Pino Felipe Princess Research Center (CIPF), ProteoRed, Valencia RU2f-Dr. Fernando Vivanco / Dr. ME Barderas Jimenez Díaz Foundation (FJD), Madrid /National Paraplegics Hospital, Toledo RU2g-Dr. Francisco Blanco Instituto de Investigacion Biomedica (INIBIC), ProteoRed, La Coruña RU2h-Dr Silvia Barceló Aragón Health Sciences Institute (IACS), Zaragoza WG1-Protein Micro Array & Peptide Standard Team RU1a (Peptide standardization Team):Dr. Manuel Fuentes Centro de Investigación del Cáncer/IBMCC (USAL/CSIC), Salamanca RU1b (Protein Micro Array and Protein expression Team): Dr. Juan P Albar National Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid WG1-Protein Micro Array & Peptide Standard Team RU1a (Peptide standardization Team):Dr. Manuel Fuentes Centro de Investigación del Cáncer/IBMCC (USAL/CSIC), Salamanca RU1b (Protein Micro Array and Protein expression Team): Dr. Juan P Albar National Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid WG3-Protein Sequencing Team RU3a-Dr. José M. Mato / Dr. Félix Elortza CIC-BioGUNE, ProteoRed, Bilbao RU3b-Dr. Joaquin Abian IIBB, CSIC ProteoRed, Barcelona RU3c-Dr. Manuel Sanchez del Pino University of Valencia, ProteoRed, Valencia RU3d-Dr. Eliandre de Oliveira Parc Científic de Barcelona (PCB), ProteoRed, Barcelona RU3e-Dr. Ignacio Casal Biology Research Center-CSIC (CIB-CSIC), ProteoRed, Madrid RU3f-Dr. Jesus M. Arizmendi Basque Country University ProteoRed, Bilba o RU3g-Dr. Juan P Albar National Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid WG3-Protein Sequencing Team RU3a-Dr. José M. Mato / Dr. Félix Elortza CIC-BioGUNE, ProteoRed, Bilbao RU3b-Dr. Joaquin Abian IIBB, CSIC ProteoRed, Barcelona RU3c-Dr. Manuel Sanchez del Pino University of Valencia, ProteoRed, Valencia RU3d-Dr. Eliandre de Oliveira Parc Científic de Barcelona (PCB), ProteoRed, Barcelona RU3e-Dr. Ignacio Casal Biology Research Center-CSIC (CIB-CSIC), ProteoRed, Madrid RU3f-Dr. Jesus M. Arizmendi Basque Country University ProteoRed, Bilba o RU3g-Dr. Juan P Albar National Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid

55. Benefit for Spain The HPP is an excellent opportunity that will provide Spain a leadership opportunity in terms of: Knowledge transfer to the National Health System as well as to the Spanish pharma and biotech companies will help to make more visible the enormous economic and social potential associated to the combination of Science, Public Health and Private companies. HPP could prove to be one of the biggest collective projects in the field of biomedicine. Taking part in this big international scientific project is an unique opportunity for our country. Big impact in the media. HPP project will help to consolidate current “cutting-edge” position of the spanish proteomics. Training of highly skilled technological teams. Increasing of the Spanish scientific network system (CIBER, RETICs, etc).

56. Aims to achieve in the 1st Chr-16 Consortium Meeting Evaluation of the strategy defined in the April 2nd S_HPP Meeting: S/MRM, AIMS, Shotgun, cell culture, protein expression, data base, bioinformatics platform, data workflow Preparation of JPR manuscript, HUPO-Boston Posters… 2012 Working plan (short and medium term)

57. HUPO CONGRESS POSTERS (I) RE: Abstract log #322 Your abstract entitled Chromosome 16 Consortium: Current Developments on the Characterization of the Proteins Encoded by the Chromosome 16" (log #322) is formally accepted for poster presentation at the HUPO 11th Annual World Congress, September 9-13, 2012 in Boston, MA (USA). RE: Abstract log #146 Your abstract entitled Chromosome 16. Transcriptomic profiling of lymphocyte B Ramos cells, MCF-7 epithelial cells and CCD18 fibroblasts (log #146) is formally accepted for poster presentation at the HUPO 11th Annual World Congress, September 9-13, 2012 in Boston, MA (USA). RE: Abstract log #368 Your abstract entitled Profiling the Chromosome 16 by high-resolution data-dependent Mass Spectrometry (log #368) is formally accepted for poster presentation at the HUPO 11th Annual World Congress, September 9-13, 2012 in Boston, MA (USA).

58. HUPO CONGRESS POSTERS (II) RE: Your abstract log# 758 for the HUPO2012 conference was submitted on 6/30/2012.The log number for your abstract is 758. Chromosome 16 Consortium: The Spanish B/D-C-HPP Initiative Juan P Albar; Jesus Fortun; Jesus Mari Arizmendi; Cristobal Belda; Ignacio Casal; Fernando Corrales; Concha Gil; Adolfo Lopez-Munain; Jesus Prieto; Jesus Rodriguez-Padial; Fernando Vivanco; Francisco J Blanco. Spanish B/D-HPP Consortium, A Coruña, Spain. RE: Abstract log #217 Your abstract entitled Automatic reporting and reproducibility analysis of ProteoRed participants in the multi-laboratory studies using the “MIAPE extractor” tool (log #217) is formally accepted for poster presentation at the HUPO 11th Annual World Congress, September 9-13, 2012 in Boston, MA (USA). RE: Abstract log# 785 Your abstract entitled Reporting and connecting experimental information through proteomics data standards. J. Alberto Medina- Aunon; Salvador Martínez de Bartolomé; Miguel A. López; Juan P. Albar Centro Nacional de Biotecnología - CSIC, Madrid, Spain for the HUPO2012 conference was submitted on 7/11/2012.